These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30484832)

  • 1. High-Density Lipoprotein-Targeted Therapies-Not Dead Yet-Reply.
    Nicholls SJ; Puri R; Nissen SE
    JAMA Cardiol; 2018 Dec; 3(12):1255-1256. PubMed ID: 30484832
    [No Abstract]   [Full Text] [Related]  

  • 2. High-Density Lipoprotein-Targeted Therapies-Not Dead Yet.
    Garcia-Ropero A; Santos-Gallego CG; Badimon JJ
    JAMA Cardiol; 2018 Dec; 3(12):1254-1255. PubMed ID: 30484828
    [No Abstract]   [Full Text] [Related]  

  • 3. High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.
    Androulakis E; Zacharia E; Papageorgiou N; Lioudaki E; Bertsias D; Charakida M; Siasos G; Tousoulis D
    Curr Cardiol Rev; 2017; 13(3):168-182. PubMed ID: 28190386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?
    Tardif JC
    J Clin Lipidol; 2010; 4(5):399-404. PubMed ID: 21122683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High density lipoprotein, apolipoprotein A-I, and coronary artery disease.
    Srivastava RA; Srivastava N
    Mol Cell Biochem; 2000 Jun; 209(1-2):131-44. PubMed ID: 10942211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of cholesterol concentrations in low-density lipoprotein, high-density lipoprotein, and high-density lipoprotein subfractions, and of apolipoproteins AI and AII, with coronary stenosis and left ventricular function.
    Kempen HJ; van Gent CM; Buytenhek R; Buis B
    J Lab Clin Med; 1987 Jan; 109(1):19-26. PubMed ID: 3098880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target.
    Lüscher TF; Landmesser U; von Eckardstein A; Fogelman AM
    Circ Res; 2014 Jan; 114(1):171-82. PubMed ID: 24385510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport.
    Duffy D; Rader DJ
    Circulation; 2006 Feb; 113(8):1140-50. PubMed ID: 16505192
    [No Abstract]   [Full Text] [Related]  

  • 9. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease.
    Maciejko JJ; Holmes DR; Kottke BA; Zinsmeister AR; Dinh DM; Mao SJ
    N Engl J Med; 1983 Aug; 309(7):385-9. PubMed ID: 6410239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic use of the high-density lipoprotein protein and peptides.
    Marchesi M; Sirtori CR
    Expert Opin Investig Drugs; 2006 Mar; 15(3):227-41. PubMed ID: 16503760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual differences in lipoprotein composition in a family with dyslipidemic hypertension with premature atheroschlerosis: deficiency of high-density lipoprotein-L and high-density lipoprotein-M "apolipoprotein-I alone" particle.
    Hughes TA; Moore MA; Joyce M; Go RC; Segrest JP; Blackwell T
    J Lab Clin Med; 1992 Jan; 119(1):57-68. PubMed ID: 1727908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency of apolipoproteins A-I and C-III and severe coronary heart disease.
    Hiasa Y; Maeda T; Mori H
    Clin Cardiol; 1986 Jul; 9(7):349-52. PubMed ID: 3089658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk.
    Asztalos BF; Horvath KV; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):2007-2015. PubMed ID: 30002062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL.
    Sutter I; Velagapudi S; Othman A; Riwanto M; Manz J; Rohrer L; Rentsch K; Hornemann T; Landmesser U; von Eckardstein A
    Atherosclerosis; 2015 Aug; 241(2):539-46. PubMed ID: 26093887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein B and apolipoprotein AI as predictors of coronary artery disease.
    Sniderman AD
    Can J Cardiol; 1988 Jul; 4 Suppl A():24A-30A. PubMed ID: 3141025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density lipoprotein and coronary heart disease: current and future therapies.
    Natarajan P; Ray KK; Cannon CP
    J Am Coll Cardiol; 2010 Mar; 55(13):1283-99. PubMed ID: 20338488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between serum amyloid A and apolipoprotein A-I in high-density lipoprotein isolated from patients with coronary heart disease.
    Wang DX; Liu H; Yan LR; Zhang YP; Guan XY; Xu ZM; Jia YH; Li YS
    Chin Med J (Engl); 2013; 126(19):3656-61. PubMed ID: 24112159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
    Schaefer JR; Schweer H; Ikewaki K; Stracke H; Seyberth HJ; Kaffarnik H; Maisch B; Steinmetz A
    Atherosclerosis; 1999 May; 144(1):177-84. PubMed ID: 10381291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of ischaemic heart disease and associations with serum lipoproteins in subjects aged 45 to 64 years. The Speedwell study.
    Bainton D; Burns-Cox CJ; Elwood PC; Lewis B; Miller NE; Morgan K; Sweetnam PM
    Br Heart J; 1982 May; 47(5):483-9. PubMed ID: 7073910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between the insertion/deletion polymorphism in the gene coding for receptor associated protein (RAP) and plasma apolipoprotein AI (apoAI) and high-density lipoprotein cholesterol (HDL) levels.
    Benes P; Muzik J; Benedík J; Elbl L; Znojil V; Vácha J
    Clin Genet; 2000 Apr; 57(4):309-10. PubMed ID: 10845573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.